<DOC>
	<DOCNO>NCT00938288</DOCNO>
	<brief_summary>The aim study determine pharmacokinetics , safety tolerability KW-3357 asymptomatic subject congenital antithrombin deficiency .</brief_summary>
	<brief_title>A Study KW-3357 Congenital Antithrombin Deficiency</brief_title>
	<detailed_description>Patients Congenital Antithrombin Deficiency increase risk venous thrombosis pulmonary embolism especially undergoing certain high risk procedure . Antithrombin replacement therapy often administer period , without low molecular weight heparin . Prior assess efficacy KW-3357 , new recombinant human antithrombin , present study determine 's pharmacokinetics , safety tolerability subject Congenital Antithrombin Deficiency currently asymptomatic undergo high-risk procedure . Up 16 evaluable subject enrol multiple investigational site period approximately 7 month .</detailed_description>
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Male female subject least 18 year age congenital Antithrombin deficiency ( AT activity â‰¤60 % normal ) stable condition without evidence acute thromboembolic event Signed IECapproved Informed Consent Form Subjects must receive infusion Antithrombin least 14 day Screening Patients reproductive potential must agree follow accepted birth control method study Subjects classify morbidly obese ( defined presence body mass index &gt; 40 kg/m2 ) Subjects participate study investigational drug within 30 day Screening within 5.5 time elimination halflife investigational drug Screening , whichever period great Subjects clinically relevant medical history current condition physical finding , ECG , laboratory value could interfere objective study safety subject Subjects use nonsteroidal antiinflammatories , fondaparinux sodium , dabigatran rivaroxaban expect treat drug study Subjects concomitant nephrotic syndrome Female subject pregnant lactate Subjects take heparin , low molecular weight heparin and/or oral anticoagulant , exception vitamin K antagonist ( eg , warfarin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Antithrombin</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hereditary Antithrombin Deficiency</keyword>
	<keyword>Congenital Antithrombin Deficiency</keyword>
</DOC>